Publications
Representative publications over last 15 years
- Lingo JJ, Reis R, Koyas A, Voigt E, Zacharias ZR, Allamargot C, Hornick EL, Raygoza Garay JA, Kaemmer CA, Elias EC, Jabbari A, Wilhelm CR, Boyden AW, Karandikar NJ, Breheny P, Meyerholz DK, Dodd RD, Houtman JCD, Darbro BW, Quelle DE. Intratumoural plasma cells mediate a pro-inflammatory response to kinase inhibition and successful immune checkpoint blockade therapy in malignant peripheral nerve sheath tumours. EBioMedicine. 2026 Sep;131:106413. PMID: 42541926 PMCID: PMC13453594
- Voigt EM, Isaacson AL, Leidinger MR, Goeken JA, Hanigan Q, Guo DF, Gasser RM, Eadie M, Babor I, Darbro BW, Paradee W, Rahmouni K, Zhao T, Breheny P, Lee E, Kim M, Meyerholz DK, Milhem M, Dodd RD, Quelle DE. Development of a Cre-inducible Rabl6a transgenic mouse model that enhances sarcoma growth in vivo. Cancers (Basel). 2026 Jul 11;18(14):2230. PMID: 42512296 PMCID: PMC1340715
- Ear PH, Hueser SA, Townsend RE, Maxwell JE, Abusada E, Chan CHF, Quelle DE, Dillon JS, Howe JR, Bellizzi AM. Variable GLP-1 receptor expression across diverse neuroendocrine neoplasms: implications for incretin therapies. Endocr Oncol. 2025 Nov 25;5(1):e250051. PMID: 41312422 PMCID: PMC12648204
- Shilyansky JS, Chan CJ, Xiao S, Gribovskaja-Rupp I, Quelle DE, Howe JR, Dillon JS, Ear PH. GLP-1R agonist promotes proliferation of neuroendocrine neoplasm cells expressing GLP-1 receptors. Surgery. 2025 Mar;179:108943. DOI: 10.1016/j.surg.2024.09.052. PMID: 39665969
- Vaughn H, Major H, Kadera E, Keck K, Dunham T, Qian Q, Brown B, Scott A, Bellizzi AM, Braun T, Breheny P, Quelle DE, Howe JR, Darbro B. Functional copy-number alterations as diagnostic and prognostic biomarkers in neuroendocrine tumors. Int J Mol Sci. 2024 Jul 9;25(14):7532. PMID: 39062773 PMCID: PMC11277019
- Kohlmeyer JL, Lingo JJ, Kaemmer CA, Scherer A, Warrier A, Voigt E, Raygoza Garay JA, McGivney GR, Brockman QR, Tang A, Calizo A, Pollard K, Zhang X, Hirbe AC, Pratilas CA, Leidinger M, Breheny P, Chimenti MS, Sieren JC, Monga V, Tanas MR, Meyerholz DK, Darbro BW, Dodd RD, Quelle DE. CDK4/6-MEK inhibition in MPNSTs causes plasma cell infiltration, sensitization to PD-L1 blockade, and tumor regression. Clin Cancer Res. 2023 Jul 6:CCR-23-0749. PMID: 37410426
- Kohlmeyer JL, Kaemmer CA, Lingo JJ, Voigt E, Leidinger MR, McGivney GR, Scherer A, Koppenhafer SL, Gordon DJ, Breheny P, Meyerholz DK, Tanas MR, Dodd RD, Quelle DE. Oncogenic RABL6A promotes NF1-associated MPNST progression in vivo. Neurooncol Adv. 2022 Apr 9;4(1):vdac047. PMID: 35571990
- Maharjan CK, Umesalma S, Kaemmer CA, Muniz VP, Bauchle C, Mott SL, Zamba KD, Breheny P, Leidinger MR, Darbro BW, Stephens SB, Meyerholz DK, and Quelle DE: RABL6A promotes pancreatic neuroendocrine tumor angiogenesis and progression in vivo. Biomedicines 9(2):633, 2021. PMCID: PMC8228095
- Kaemmer CA, Umesalma S, Maharjan CK, Moose DL, Narla G, Mott SL, Zamba GKD, Breheny P, Darbro BW, Bellizzi AM, Henry MD, and Quelle DE: Development and comparison of novel bioluminescent mouse models of pancreatic neuroendocrine neoplasm metastasis. Sci Rep 11(1):10252, 2021. PMCID: PMC8119958
- Scott AT, Weitz M, Breheny PJ, Ear PH, Darbro B, Brown BJ, Braun TA, Li G, Umesalma S, Kaemmer CA, Maharjan CK, Quelle DE, Bellizzi AM, Chandrasekharan C, Dillon JS, O’Dorisio TM, and Howe JR. Gene Expression signatures identify novel therapeutics for metastatic pancreatic neuroendocrine tumors. Clin Cancer Res 26(8):2011-2021, 2020. PMCID: PMC7165057
- Kohlmeyer JL, Kaemmer CA, Pulliam C, Maharjan CK, Moreno Samayoa A, Major H, Cornick K, Knepper-Adrian V, Khanna R, Sieren JC, Leidinger MR, Meyerholz DK, Zamba G, Weimer JM, Dodd RD, Darbro BW, Tanas MR, and Quelle DE. RABL6A is an essential driver of MPNSTs that negatively regulates the RB1 pathway and sensitizes tumor cells to CDK4/6 inhibitors. Clin Cancer Res 26(12):2997-3011, 2020. PMCID: PMC7299809
- Umesalma S, Kaemmer CA, Kohlmeyer JL, Letney B, Schab AM, Reilly JA, Sheehy RM, Hagen J, Tiwari N, Zhan F, Leidinger MR, O'Dorisio TM, Dillon J, Merrill RA, Meyerholz DK, Perl AL, Brown BJ, Braun TA, Scott AT, Ginader T, Taghiyev AF, Zamba GK, Howe JR, Strack S, Bellizzi AM, Narla G, Darbro BW, Quelle FW, Quelle DE. RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth. J Clin Invest. 2019 Mar 4;130. pii: 123049. PMID: 30721156
- White KA, Swier VJ, Cain JT, Kohlmeyer JL, Meyerholz DK, Tanas MR, Uthoff J, Hammond E, Li H, Rohret FA, Goeken A, Chan CH, Leidinger MR, Umesalma S, Wallace MR, Dodd RD, Panzer K, Tang AH, Darbro BW, Moutal A, Cai S, Li W, Bellampalli SS, Khanna R, Rogers CS, Sieren JC, Quelle DE, Weimer JM. A porcine model of neurofibromatosis type 1 that mimics the human disease. JCI Insight. 2018 Jun 21;3(12). pii: 120402. PMID: 29925695
- Pardo M, Yu L, Shen S, Tate P, Bode D, Letney BL, Quelle DE, Skarnes W, Choudhary JS. Myst2/Kat7 histone acetyltransferase interaction proteomics reveals tumour-suppressor Niam as a novel binding partner in embryonic stem cells. Sci Rep. 2017 Aug 15;7(1):8157. PMID: 28811661
- Reed SM, Quelle DE. p53 Acetylation: Regulation and Consequences. Cancers (Basel). 2014 Dec 23;7(1):30-69. doi: 10.3390/cancers7010030. Review. PMID: 25545885
- Reed SM, Hagen J, Muniz VP, Rosean TR, Borcherding N, Sciegienka S, Goeken JA, Naumann PW, Zhang W, Tompkins VS, Janz S, Meyerholz DK, Quelle DE. NIAM-deficient mice are predisposed to the development of proliferative lesions including B-cell lymphomas. PLoS One. 2014 Nov 13;9(11):e112126. PMID: 25393878
- Hagen J, Muniz VP, Falls KC, Reed SM, Taghiyev AF, Quelle FW, Gourronc FA, Klingelhutz AJ, Major HJ, Askeland RW, Sherman SK, O'Dorisio TM, Bellizzi AM, Howe JR, Darbro BW, Quelle DE. RABL6A promotes G1-S phase progression and pancreatic neuroendocrine tumor cell proliferation in an Rb1-dependent manner. Cancer Res. 2014 Nov 15;74(22):6661-70. PMID: 25273089
- Sieren JC, Meyerholz DK, Wang XJ, Davis BT, Newell JD Jr, Hammond E, Rohret JA, Rohret FA, Struzynski JT, Goeken JA, Naumann PW, Leidinger MR, Taghiyev A, Van Rheeden R, Hagen J, Darbro BW, Quelle DE, Rogers CS. Development and translational imaging of a TP53 porcine tumorigenesis model. J Clin Invest. 2014 Sep;124(9):4052-66. PMID: 25105366
- Reed SM, Hagen J, Tompkins VS, Thies K, Quelle FW, Quelle DE. Nuclear interactor of ARF and Mdm2 regulates multiple pathways to activate p53. Cell Cycle. 2014;13(8):1288-98. PMID: 24621507
- Zhang X, Hagen J, Muniz VP, Smith T, Coombs GS, Eischen CM, Mackie DI, Roman DL, Van Rheeden R, Darbro B, Tompkins VS, Quelle DE. RABL6A, a novel RAB-like protein, controls centrosome amplification and chromosome instability in primary fibroblasts. PLoS One. 2013 Nov 25;8(11):e80228. PMID: 24282525
- Muniz VP, Askeland RW, Zhang X, Reed SM, Tompkins VS, Hagen J, McDowell BD, Button A, Smith BJ, Weydert JA, Mezhir JJ, Quelle DE. RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients. Genes Cancer. 2013 Jul;4(7-8):273-84. PMID: 24167655
- Muniz VP, Barnes JM, Paliwal S, Zhang X, Tang X, Chen S, Zamba KD, Cullen JJ, Meyerholz DK, Meyers S, Davis JN, Grossman SR, Henry MD, Quelle DE. The ARF tumor suppressor inhibits tumor cell colonization independent of p53 in a novel mouse model of pancreatic ductal adenocarcinoma metastasis. Mol Cancer Res. 2011 Jul;9(7):867-77. PMID: 21636682